Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, College of Medicine, Chicago, IL 60607, USA.
Oncogene. 2013 Sep 5;32(36):4304-12. doi: 10.1038/onc.2012.427. Epub 2012 Oct 1.
Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase expressed in epithelial cancers. Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation. Relocalization of PTK6 in prostate cancers contributes to increased growth. Although not expressed in normal breast or ovary, PTK6 promotes anchorage-independent survival of breast and ovarian tumor cells. We identified several potential PTK6 substrates in the human SW620 colon cancer cell line using mass spectrometry, including FAK (focal adhesion kinase). We show that FAK is a direct substrate of PTK6 in vitro and in vivo. Expression of membrane-targeted active PTK6 (Palm-PTK6-YF) induces constitutive activation of FAK and cell morphology changes, which are independent of SRC family kinases in Src-/-, Yes-/-, Fyn-/- (SYF) mouse embryonic fibroblasts (MEFs). Palm-PTK6-YF expressing SYF cells are transformed and overcome contact inhibition, form colonies in transformation assays, proliferate in suspension and form tumors in a xenograft model. Expression of FAK and Palm-PTK6-YF in Fak-/- MEFs synergistically activates AKT and protects cells against anoikis. However, expression of Palm-PTK6-YF in Akt1/2-/- MEFs fails to protect cells from anoikis, indicating AKT is critical in PTK6 and FAK-mediated survival signaling. In a conditional Pten knockout murine prostate cancer model, we identify prostate epithelial cells with enhanced activation of endogenous PTK6 and FAK at the plasma membrane. Knockdown of PTK6 in the PC3 human prostate cancer cell line disrupts FAK and AKT activation and promotes anoikis, which can be rescued by exogenous expression of FAK. Our data reveal important roles for a PTK6-FAK-AKT signaling axis in promoting anchorage-independent cell survival.
蛋白酪氨酸激酶 6(PTK6)是一种在上皮癌中表达的非受体酪氨酸激酶。Ptk6 的破坏通过阻止信号转导和转录激活因子 3 的激活,减少了小鼠中氧化偶氮甲烷诱导的结肠癌发生。PTK6 在前列腺癌中的重新定位导致生长增加。尽管在正常乳腺或卵巢中不表达,但 PTK6 促进了乳腺和卵巢肿瘤细胞的无锚定生存。我们使用质谱法在人 SW620 结肠癌细胞系中鉴定了几种潜在的 PTK6 底物,包括 FAK(粘着斑激酶)。我们表明,FAK 是 PTK6 的体外和体内的直接底物。表达膜靶向活性 PTK6(Palm-PTK6-YF)诱导 FAK 的组成性激活和细胞形态变化,这在 Src-/-, Yes-/-, Fyn-/-(SYF)小鼠胚胎成纤维细胞(MEFs)中独立于 SRC 家族激酶。表达 Palm-PTK6-YF 的 SYF 细胞被转化并克服接触抑制,在转化测定中形成集落,在悬浮液中增殖并在异种移植模型中形成肿瘤。 Fak-/-MEFs 中 FAK 和 Palm-PTK6-YF 的表达协同激活 AKT 并保护细胞免受凋亡。然而,在 Akt1/2-/-MEFs 中表达 Palm-PTK6-YF 不能保护细胞免受凋亡,表明 AKT 在 PTK6 和 FAK 介导的存活信号中至关重要。在条件性 Pten 敲除的小鼠前列腺癌模型中,我们在前列腺上皮细胞中鉴定出增强的内源性 PTK6 和 FAK 在质膜上的激活。在 PC3 人前列腺癌细胞系中敲低 PTK6 会破坏 FAK 和 AKT 的激活并促进凋亡,这可以通过外源性表达 FAK 来挽救。我们的数据揭示了 PTK6-FAK-AKT 信号轴在促进无锚定细胞存活中的重要作用。